Computational studies on transthyretin

Current Medicinal Chemistry

Volumn 19, Issue 15, 2012, Pages 2380-2387

  Ortore, G ^a   Martinelli, A ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Amyloid fibril; Computational chemistry; Docking; Molecular dynamics; Pharmacophoric model; SAR; Transthyretin; Virtual screening

Indexed keywords

PERFLUORO COMPOUND; PREALBUMIN;

ARTICLE; BINDING SITE; CRYSTAL STRUCTURE; FAMILIAL AMYLOIDOSIS; HUMAN; HYDROPHOBICITY; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; PHARMACOPHORE; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN UNFOLDING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECEIVER OPERATING CHARACTERISTIC; SCREENING TEST; STRUCTURE ACTIVITY RELATION;

EID: 84860681450     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712800269344     Document Type: Article

References (52)

1. Yang, M.; Lei, M.; Huo, S. Why is Leu55-Pro55 transthyretin variant the most amyloidogenic: Insights from molecular dynamics simulations of transthyretin monomers. Protein Sci., 2003, 12, 1222-1231. (Pubitemid 36597509)
2. Lei, M.; Yang, M.; Huo, S. Intrinsic versus mutation dependent instability/flexibility: A comparative analysis of the structure and dynamics of wild-type transthyretin and its pathogenic variants. J. Struct. Biol., 2004, 148 153-168. (Pubitemid 39346005)
3. Yang, M.; Lei, M.; Bruschweiler, R.; Huo, S. Initial conformational changes of human transthyretin under partially denaturing conditions. Biophys. J., 2005, 89, 433-443. (Pubitemid 41098298)
4. Yang, M.; Yordanov, B.; Levy, Y.; Bruschweiler, R.; Huo, S. The sequencedependent unfolding pathway plays a critical role in the amyloidogenicity of transthyretin. Biochemistry, 2006, 45, 11992-12002. (Pubitemid 44497824)
5. Armen, R. S.; Alonso, D. O. V.; Daggett, V. Pauling and Corey's a-pleated sheet structure may define the prefibrillar amyloidogenic intermediate in amyloid disease. Proc. Natl. Acad. Sci., 2004, 101, 11622-11627. (Pubitemid 39095346)
6. Armen, R. S.; Alonso, D. O. V.; Daggett, V. Anatomy of an amyloidogenic intermediate: Conversion of β-sheet to a-sheet structure in transthyretin at acidic pH. Structure, 2004, 12, 1847-1863. (Pubitemid 39298968)
7. Steward, R. E.; Armen, R. S.; Daggett, V. Different disease-causing mutations in transthyretin trigger the same conformational conversion. Protein Eng. Des. Sel., 2008, 21, 187-195. (Pubitemid 351323356)
8. Berrar, D.; Stahl, F.; Silva, C.; Rodrigues, J. R.; Brito, R. M. M.; Dubitzky, W. Towards data warehousing and mining of protein unfolding simulation data. J. Clin. Monitor Comp., 2005, 19, 307-317. (Pubitemid 43055304)
9. Rodrigues, J. R.; Simoes, C. J. V.; Silva, C. G.; Brito, R. M. M. Potentially amyloidogenic conformational intermediates populate the unfolding landscape of transthyretin: Insights from molecular dynamics simulations. Protein Sci., 2010, 19, 202-219.
10. Cendron, L.; Trovato, A.; Seno, F.; Folli, C.; Alfieri, B.; Zanotti, G.; Berni, R. Amyloidogenic Potential of Transthyretin Variants. Insights from structural and computational analyses. J. Biol. Chem., 2009, 284, 25832-25841.
11. Bernhard, S.; Noe, F. Optimal identification of semi-rigid domains in macromolecules from molecular dynamics simulation. PLoS ONE, 2010, 5, e10491.
12. Banerjee, A.; Bairagya, H. R.; Mukhopadhyay, B. P.; Nandi, T. K.; Bera, A. K. Structural insight to mutated Y116S transthyretin by molecular dynamics simulation. Indian J. Biochem. Bio., 2010, 47, 197-202.
13. Wang, H.; Tang, Y.; Lei, M. Models for binding cooperativities of inhibitors with transthyretin. Arch. Biochem. Biophys., 2007, 466, 85-97. (Pubitemid 47405074)
14. Liu, K.; Kelly, J. W.; Wemmer, D. E. Native state hydrogen exchange study of suppressor and pathogenic variants of transthyretin. J. Mol. Biol., 2002, 320, 821-832. (Pubitemid 34729408)
15. Correia, B. E.; Luoreiro-Ferreira, N.; Rodrigues, J. R.; Brito, R. M. M. A structural model of an amyloid protofilament of Transthyretin. Protein Sci., 2006, 15, 28-32. (Pubitemid 43004230)
16. Swain, M.; Ostropytskyy, V.; Silva, C. G.; Stahl, F.; Riche, O.; Brito, R. M. M.; Dubitzky, W. Grid computing solutions for distributed repositories of protein folding and unfolding simulations. Proceedings of the 8th International Conference Computational Science-ICCS 2008, Kraków, Poland, June 23-25, 2008, Part III; Bubak, M.; van Albada, G.D.; Dongarra, J.; Sloot, P.M.A., Eds; Lecture Notes in Computer Science, 5103, 2008, pp. 70-79
17. Quintas, A.; Vaz, D. C.; Cardoso, I.; Saraiva, M. J.; Brito, R. M. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J. Biol. Chem., 2001, 276, 27207-13.
18. Wang, R.; Lu, Y.; Wang, S. Comparative evaluation of 11 scoring functions for molecular docking. J. Med. Chem,. 2003, 46, 2287-2303. (Pubitemid 36637914)
19. Gorelik, B.; Goldblum, A. High quality binding modes in docking ligands to proteins. Proteins, 2008, 71, 1373-1385.
20. Bordogna, A.; Pandini, A.; Bonati, L. Predicting the accuracy of protein-ligand docking on homology models. J. Comput. Chem., 2011, 32, 81-98.
21. Maia, F.; Almeida, M.; Gales, L.; Kijjoa, A.; Pinto, M. M.; Saraiva, M. J.; Damas, A. M. The binding of xanthone derivatives to transthyretin. Biochem. Pharmacol., 2005, 70, 1861-1869. (Pubitemid 41612017)
22. Gupta, S.; Chhibber, M.; Sinha, S.; Surolia, A. Design of mechanism-based inhibitors of transthyretin amyloidosis: Studies with biphenyl ethers and new structural templates. J. Med. Chem., 2007, 50, 5589-5599. (Pubitemid 350106015)
23. Rossi, M.; Caruso, F.; Opazo, C.; Salciccioli, J. Crystal and molecular structure of piceatannol; scavenging features of resveratrol and piceatannol on hydroxyl and peroxyl radicals and docking with transthyretin. J. Agric. Food Chem., 2008, 56, 10557-10566.
24. Cao, J.; Lin, Y.; Guo, L.-H.; Zhang, A.-Q.; Wei, Y.; Yang, Y. Structurebased investigation on the binding interaction of hydroxylated polybrominated diphenyl ethers with thyroxine transport proteins. Toxicology, 2010, 277, 20-28.
25. Simoes, C. J. V.; Mukherjee, T.; Brito, R. M. M.; Jackson, R. M. Toward the discovery of functional transthyretin amyloid inhibitors: Application of virtual screening methods. J. Chem. Inf. Model., 2010, 50, 1806-1820.
26. Palaninathan, S. K.; Mohamedmohaideen, N. N.; Orlandini, E.; Ortore, G.; Nencetti, S.; Lapucci, A.; Rossello, A.; Freundlich, J. S.; Sacchettini, J. C. Novel transthyretin amyloid fibril formation inhibitors: Synthesis, biological evaluation, and x-ray structural analysis. PlosONE, 2009, 4, e6290.
27. Blasi, D.; Arsequell, G.; Valencia, G.; Nieto, J.; Planas, A.; Pinto, M.; Centeno, N. B.; Abad-Zapatero, C.; Quintana, J. Retrospective mapping of SAR data for TTR protein in chemico-biological space using ligand efficiency indices as a guide to drug discovery strategies. Mol. Inf., 2011, 30, 161-167.
28. Natesan, S.; Wang, T.; Lukacova, V.; Bartus, V.; Khandelwal, A.; Balaz, S. Rigorous treatment of multispecies multimode ligand-receptor interactions in 3D-QSAR: CoMFA analysis of thyroxine analogs binding to transthyretin. J. Chem. Inf. Model., 2011, 51, 1132-1150.
29. Blasi, D.; Pinto, M.; Nieto, J.; Arsequell, G.; Valencia, G.; Planas, A.; Centeno, N. B.; Quintana, J. Drug discovery targeted at transthyretin cardiac amyloidosis: Rational design, synthesis, and biological activity of new transthyretin amyloid inhibitors. Amyloid, 2011, 18, 50-52.
30. Mairal, T.; Nieto, J.; Pinto, M.; Almeida, M. R.; Gales, L.; Ballesteros, A.; Barluenga, J.; Perez, J. J.; Vazquez, J. T.; Centeno, N. B.; Saraiva, M. J.; Damas, A. M.; Planas, A.; Arsequell, G.; Valencia, G. Iodine atoms: A new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors. PlosONE, 2009, 4 (1), e4124.
31. Hammarstrom, P.; Jiang, X.; Hurshman, A. R.; Powers, E. T.; Kelly, J. W. Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proc. Natl. Acad. Sci., 2002, 99, 16427-32. (Pubitemid 35470989)
32. Schneider, F.; Hammarstrom, P.; Kelly, J. W. Transthyretin slowly exchanges subunits under physiological conditions: A convenient chromatographic method to study subunit exchange in oligomeric proteins. Protein Sci., 2001, 10, 1606-13. (Pubitemid 32667054)
33. Hurshman, A. R.; White, J. T.; Powers, E. T.; Kelly, J. W. Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry, 2004, 43, 7365-81. (Pubitemid 38745754)
34. Lai, Z.; Colon, W.; Kelly, J. W. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry, 1996, 35, 6470-82. (Pubitemid 26164080)
35. Serag, A. A.; Altenbach, C.; Gingery, M.; Hubbell, W. L.; Yeates, T. O. Identification of a subunit interface in transthyretin amyloid fibrils: Evidence for self-assembly from oligomeric building blocks. Biochemistry, 2001, 40, 9089-96. (Pubitemid 32730029)
36. Serag, A. A.; Altenbach, C.; Gingery, M.; Hubbell, W. L.; Yeates, T. O. Arrangement of subunits and ordering of β-strands in an amyloid sheet. Nat. Struct. Biol., 2002, 9, 734-739.
37. Olofsson, A.; Ippel, J. H.; Wijmenga, S. S.; Lundgren, E.; Ohman, A. Probing solvent accessibility of transthyretin amyloid by solution NMR spectroscopy. J. Biol. Chem., 2004, 279, 5699-5707. (Pubitemid 38220599)
38. Malinchik, S. B.; Inouye, H.; Szumowski, K. E.; Kirschner, D. A. Structural analysis of Alzheimer's b(1-40) amyloid: Protofilament assembly of tubular fibrils. Biophys. J., 1998, 74, 537-545. (Pubitemid 28041781)
39. Jiang, X.; Smith, C. S.; Petrassi, H. M.; Hammarstrom, P.; White, J. T.; Sacchettini, J. C.; Kelly, J. W. An engineered transthyretin monomer that is nonamyloidogenic, Unless It Is Partially Denatured. Biochemistry, 2001, 40, 11442-11452. (Pubitemid 32911287)
40. Hamilton, J. A.; Steinrauf, L. K.; Braden, B. C.; Liepnieks, J.; Benson, M. D.; Holmgren, G.; Sandgren, O.; Steen, L. The x-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30-Met variant to 1.7-A resolution. J. Biol. Chem., 1993, 268, 2416-2424. (Pubitemid 23057860)
41. Trivella, D. B. B.; Sairre, M. I.; Foguel, D.; Lima, L. M. T. R.; Polikarpov, I. The binding of synthetic triiodo L-thyronine analogs to human transthyretin: Molecular basis of cooperative and non-cooperative ligand recognition. J. Struct. Biol., 2011, 173, 323-332.
42. Sørensen, J.; Hamelberg, D.; Schiøtt, B.; McCammon, J. A. Comparative MD analysis of the stability of transthyretin providing insight into the fibrillation mechanism. Biopolymers, 2007, 86, 73-82. (Pubitemid 46716696)
43. Surolia, A. Mechanism-based inhibition of transthyretin amyloidosis using biphenyl ether derivatives U.S. Patent 2010/0190832, Jul 29, 2010.
44. Castillo, V.; Ventura, S. Amyloidogenic regions and interaction surfaces overlap in globular proteins related to conformational diseases. PLoS Comput. Biol., 2009, 5 (8), e1000476.
45. Ghosh, J. G.; Clark, J. I. Composition and methods for treatment of protein misfolding and protein aggregation deseases. U.S. Patent 2007/0185028, Aug. 9, 2007.
46. Eisenberg, D. S.; Sievers, S. A.; Karanicolas, J.; Baker, D. Structure-based design of peptide inhibitors of amyloid fibrillation U.S. Patent 2010/0204085, Aug. 12, 2010.
47. Kohlhoff, K. J.; Zurdo, J.; Vendruscolo, M. Method for predicting protein aggregation and designing aggregation inhibitors PCT Int. Appl. WO 2008/015384, Feb. 7, 2008.
48. Weiss, J. M.; Andersson, P. L.; Lamoree, M. H.; Leonards, P. E. G.; van Leeuwen, S. P. J.; Hamers, T. Competitive binding of poly-and perfluorinated compounds to the thyroid hormone transport protein transthyretin. Toxicol. Sci., 2009, 109, 206-216.
49. Pinto, M.; Blasi, D.; Nieto, J.; Arsequell, G.; Valencia, G.; Planas, A.; Quintana, J.; Centeno, N. Ligand-binding properties of human transthyretin. Amyloid, 2011, 18, 46-49.
50. Ortore, G.; Orlandini, E.; Tuccinardi, T.; Romagnoli, E.; Martinelli, A. In: Design of transthyretin amyloidosis inhibitors: A docking and virtual screening approach. Proceedings of Frontiers in CNS and Oncology Medicinal Chemistry-ACS-EFMC, Siena, Italy, October 7-9, 2007; p51.
51. Leone, V.; Marinelli, F.; Carloni, P. Targeting biomolecular flexibility with metadynamics. Curr. Opin. Struc. Biol., 2010, 20, 148-154.
52. Alhamadsheh, M. M.; Connelly, S.; Cho, A.; Reixach, N.; Powers, E. T.; Pan, D. W.; Wilson, I. A.; Kelly, J. W.; Graef, I. A. Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity. Sci. Transl. Med., 2011, 3, 97ra81.